Search research articles
Contact Us
Filters
Showing results (191-200 of 206) with videos related to
Page
of 21
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 12, 2011
Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor
Lichuan Liu, Jason S Halladay, Young Shin, et al.
ACS Medicinal Chemistry Letters
|
April 16, 2020
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
Peter Blomgren, Jayaraman Chandrasekhar, Julie A Di Paolo, et al.
ACS Medicinal Chemistry Letters
|
March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation
Julie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Physical Review Letters
|
August 8, 2018
Search for the Neutron Decay n→X+γ, Where X is a Dark Matter Particle
Z Tang, M Blatnik, L J Broussard, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834
Wendy B Young, James Barbosa, Peter Blomgren, et al.
Journal of Viral Hepatitis
|
April 14, 2006
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*
N Bräu, E J Bini, S Currie, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability
Wendy B Young, James Barbosa, Peter Blomgren, et al.
JCI Insight
|
April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritis
Arna Katewa, Yugang Wang, Jason A Hackney, et al.
Journal of Medicinal Chemistry
|
September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
ACS Medicinal Chemistry Letters
|
June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties
Xiaojing Wang, James Barbosa, Peter Blomgren, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 206) with videos related to
Sort By:
Page
of 21
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 12, 2011
Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor
Lichuan Liu, Jason S Halladay, Young Shin, et al.
ACS Medicinal Chemistry Letters
|
April 16, 2020
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
Peter Blomgren, Jayaraman Chandrasekhar, Julie A Di Paolo, et al.
ACS Medicinal Chemistry Letters
|
March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation
Julie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Physical Review Letters
|
August 8, 2018
Search for the Neutron Decay n→X+γ, Where X is a Dark Matter Particle
Z Tang, M Blatnik, L J Broussard, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834
Wendy B Young, James Barbosa, Peter Blomgren, et al.
Journal of Viral Hepatitis
|
April 14, 2006
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*
N Bräu, E J Bini, S Currie, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability
Wendy B Young, James Barbosa, Peter Blomgren, et al.
JCI Insight
|
April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritis
Arna Katewa, Yugang Wang, Jason A Hackney, et al.
Journal of Medicinal Chemistry
|
September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
ACS Medicinal Chemistry Letters
|
June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties
Xiaojing Wang, James Barbosa, Peter Blomgren, et al.
Page
of 21